Characterization of specific CD4 and CD8 T-cell responses in QuantiFERON TB Gold-Plus TB1 and TB2 tubes

Allen, Nadia; Swarbrick, Gwendolyn; Cansler, Meghan; Null, Megan; Salim, Hiam; Miyamasu, Misato; Howard, Jenny; Boyle, Jeffrey; Lewinsohn, David; Lewinsohn, Deborah A.

doi:10.1016/j.tube.2018.10.014

Cited by 14 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TB1 tube in the QFT-Plus test version contains long peptides derived from the mycobacterial antigens designated ESAT 6 and CFP-10; these antigens are thought to primarily elicit a CD4 T-cell response ( 5 ). The TB2 antigen tube contains the same components as the TB1 tube and, in addition, peptides that induce CD8 release of IFN-γ ( 5 , 7 ). These M. tuberculosis -specific CD8 + cells have been detected in both active TB and LTBI patients ( 5 , 7 ).…”

Section: Discussionmentioning

confidence: 99%

“…The QFT-Plus test utilizes two different TB-specific antigen-coated tubes instead of the one-tube design used in the prior-generation QFT-GIT ( 5 , 6 ). The TB1 antigen tube in the QFT-Plus assay system elicits cell-mediated immunity (CMI) responses from CD4 + helper lymphocytes, and the TB2 antigen tube elicits CMI responses from both CD4 + T-helper and CD8 + lymphocytes ( 5 , 7 ). The TB2 tube may improve sensitivity for TB immune responses, although additional studies are warranted to confirm this.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results

Clark

Master

et al. 2021

Microbiol Spectr

View full text Add to dashboard Cite

Both the QuantiFERON-TB Gold Plus (QFT-Plus) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) tests are interferon gamma (IFN-γ) release assays (IGRAs) intended to detect in vitro cell-mediated immune responses to Mycobacterium tuberculosis antigens. In this study, we retrospectively analyzed performance data for both the QFT-GIT and QFT-Plus test systems from over 2 million samples.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results

Clark

Master

et al. 2021

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…These findings suggest that the method of subtracting the TB1 IFN-␥ levels from the TB2 levels may over-or underestimate the CD8 ϩ T-cell response. A recent study concluded that CD8 ϩ T-cell clones showed specific and targeted responses to the CFP-10 epitopes in the QFT-Plus TB2 tube (19). However, one of the CD8 ϩ T-cell-responsive CFP-10 epitopes had a significant overlap with the CD4 ϩ T-cell-responsive CFP-10 epitope.…”

Section: Discussionmentioning

confidence: 99%

Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection

et al. 2019

View full text Add to dashboard Cite

The fourth-generation QuantiFERON test for tuberculosis infection, QuantiFERON-TB Gold Plus (QFT-Plus) has replaced the earlier version, QuantiFERON-TB Gold In-Tube (QFT-GIT). A clinical need exists for information about agreement between QFT-Plus and other tests. We conducted this study to assess agreement of test results for QFT-Plus with those of QuantiFERON-TB Gold In-Tube (QFT-GIT), T-SPOT.TB (T-SPOT), and the tuberculin skin test (TST). Persons at high risk of latent tuberculosis infection (LTBI) and/or progression to tuberculosis (TB) disease were enrolled at the 10 sites of the Tuberculosis Epidemiologic Studies Consortium from October 2016 through May 2017; each participant received all four tests. Cohen’s kappa (κ) and Wilcoxon signed-rank test compared qualitative and quantitative results of QFT-Plus with the other tests. Test results for 506 participants showed 94% agreement between QFT-Plus and QFT-GIT, with 19% positive and 75% negative results. When the tests disagreed, it was most often in the direction of QFT-GIT negative/QFT-Plus positive. QFT-Plus had similar concordance as QFT-GIT with TST (77% and 77%, respectively) and T-SPOT (92% and 91%, respectively). The study showed high agreement between QFT-GIT and QFT-Plus in a direct comparison. Both tests had similar agreement with TST and T-SPOT.

show abstract

“…QFTP includes two antigen tubes, TB1 and TB2 which contain specific Mycobacterium tuberculosis (MTB) peptides. TB1 and TB2 are designed to target cell mediated responses from cluster of differentiation (CD) 4 T-cells and CD8 T-cells, respectively [ 11 ].…”

Section: Methodsmentioning

confidence: 99%

Prevalence of latent tuberculosis infection and feasibility of TB preventive therapy among Thai prisoners: a cross-sectional study

Gatechompol

Harnpariphan²,

Supanan³

et al. 2021

BMC Public Health

View full text Add to dashboard Cite

Background Prisons are considered as major reservoirs for tuberculosis. Preventive therapy for latent TB infection (LTBI) is an adjunctive strategy to control TB. However, LTBI data in Thai prisoners is limited. This study assessed the prevalence of LTBI and feasibility of isoniazid preventive therapy (IPT). Methods A cross-sectional study was conducted among prisoners in Klong Prem Central Prison, Bangkok. Participants were screened for active TB by questionnaire and chest X-ray. LTBI was evaluated by Tuberculin skin test (TST) and QuantiFERON-TB Gold Plus (QFTP) among subgroup. Participants with positive TST or QFTP were considered to have LTBI. Participants with LTBI were offered IPT. Results From August 2018–November 2019, 1002 participants were analyzed. All participants were male with a median age of 38 (IQR 32–50) years. LTBI identified by either TST/QFTP was present in 466 (46.5%) participants. TST was positive in 359 (36%) participants. In the subgroup of 294 participants who had both TST and QFTP results, 181/294 (61.6%) tested positive by QFTP. Agreement between TST and QFTP was 55.1% (Kappa = 0.17). The risk factors associated with LTBI were previous incarceration (aOR 1.53, 95%CI, 1.16–2.01, p = 0.002), history of prior active TB (aOR 3.02, 95%CI, 1.74–5.24, p < 0.001) and duration of incarceration ≥10 years (aOR 1.86, 95%CI, 1.24–2.79, p = 0.003). Majority of LTBI participants (82%) agreed to take IPT. Three hundred and 56 (93%) participants completed treatment whereas 27 (7%) participants discontinued IPT due to the side effects of INH. Conclusion This is the first study to evaluate the prevalence of LTBI and feasibility of IPT among Thai prisoners. LTBI prevalence in male prisoners in Thailand is high. LTBI screening and treatment should be implemented together with other preventive components.

show abstract

Characterization of specific CD4 and CD8 T-cell responses in QuantiFERON TB Gold-Plus TB1 and TB2 tubes

Cited by 14 publications

References 13 publications

Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results

Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results

Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection

Prevalence of latent tuberculosis infection and feasibility of TB preventive therapy among Thai prisoners: a cross-sectional study

Contact Info

Product

Resources

About